Oncology Peer Review On-The-Go: First-Line Therapeutic Options in Small Cell Lung Cancer
In the first episode of a 4-part series, CancerNetwork® spoke with Wade Iams, MD, about the various first-line treat options that are available for patients with small cell lung cancer.
In this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork® spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer (SCLC). Iams spotlighted the current first-line therapies that are available for patients with SCLC and the factors considered for treating patients in the first-line setting. He also discussed the phase 3 IMpower133 trial (NCT02763579) evaluating the safety and efficacy of atezolizumab (Tecentriq) in combination with carboplatin and etoposide for patients with extensive stage SCLC and the phase 3 CASPIAN trial (NCT03043872) examining the efficacy and safety of durvalumab (Imfinzi) with or without tremelimumab combined with platinum-based chemotherapy for patients with extensive stage SCLC.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
